Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

Inclusion Criteria: * Male or female 18 years of age or older at the time of enrollment. * Patients hospitalized with a positive RT-PCR for SARS-CoV-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe COVID-19 infection as defined by NIH COVID-19 Severity Categorization (8): * Moderate illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen SpO2≥ 94% on room air at sea level. * Severe illness: Individuals who have SpO2 \<94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \<300 mm Hg, respiratory frequency \>30 breaths/min, or lung infiltrates \>50%. * Patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. * Patients with hematologic malignancies or solid tumors are eligible. * Patients with autoimmune disorders are eligible. * Patients with immunodeficiency and organ or stem cell transplant recipients are eligible. * Patients with acute or chronic renal injury/failure are eligible. * Patients with neutropenia/lymphopenia are eligible. * Patients with elevated liver function tests are eligible. * Women who are not taking contraception are eligible. * Patients who are currently or have recently received steroids and/or remdesivir are eligible. * Patient agrees to not participate in another clinical trial for the treatment of COVID-19 through end of study period. Exclusion Criteria: * Patients who do not require inpatient admission for COVID-19 infection. * Patients who require invasive mechanical ventilation at time of enrollment. * A pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. * Pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). * Allergy to Dupilumab or its excipients. * Received any of the following in the two weeks prior to screening as treatment of COVID-19: * small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.); * monoclonal antibodies targeting cytokines (e.g., TNF inhibitors, anti-interleukin-1 \[IL-1\], anti-IL-6 \[or sarilumab\], etc.); * monoclonal antibodies targeting T-cells or B-cells as treatment for COVID-19; * Any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. * Current acute parasitic helminth infection or history of chronic parasitic infection. * History of ocular scleritis, uveitis, keratitis or recent (\<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. * Have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. Note: Use of non-live (inactivated) vaccinations is allowed for all subjects.